Intro

This chapter analyzes recent earnings reports from major companies, emphasizing Meta's strong performance and Eli Lilly's challenges with GLP-1 drugs. It also addresses Supermicro's issues with its auditor, raising questions about its future stability.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app